Advertisement

Topics

Optic Nerve Disorders Drug Development Pipeline Review, 2018 [Report Updated: 26102018] Prices from USD $3995

03:02 EST 12 Jan 2019 | BioPortfolio Reports

Optic Nerve Disorders Drug Development Pipeline Review, 2018


Summary


This report provides an overview of the pipeline landscape for disorders of the optic nerve, the bundle of nerve fibers that transmits visual information from the eye to the brain. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for optic neuropathy, glaucoma, Leber's hereditary optic neuropathy LHON and optic neuritis, and features dormant and discontinued products.


Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 10 products in development for this indication.


Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. Signs and symptoms include eye pain, nausea and vomiting accompanying the severe eye pain, sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye. There are 13 products in development for this indication.


LHON is an inherited form of vision loss. This condition usually begins in a person's teens or twenties. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. There are 16 products in development for this indication.


Optic neuritis refers to inflammation of the optic nerve. Symptoms include pain, vision loss, dyschromatopsia impaired ability to perceive colors and flashing lights. There are 12 products in development for this indication.


Molecular targets acted on by products in development for optic nerve disorders include kinases, growth factors and cannabinoid receptors. Companies operating in this pipeline space include NicOx SA Regeneron Pharmaceuticals and Amgen.


Scope


Which companies are the most active within each pipeline?

Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

What are the most important RD milestones and data publications to have happened in this disease area?


Reasons to buy


Understand the overall pipeline, with an ataglance overview of all products in therapeutic development for each indication

Assess the products in development in granular detail, with an uptodate overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Original Article: Optic Nerve Disorders Drug Development Pipeline Review, 2018 [Report Updated: 26102018] Prices from USD $3995

NEXT ARTICLE

More From BioPortfolio on "Optic Nerve Disorders Drug Development Pipeline Review, 2018 [Report Updated: 26102018] Prices from USD $3995"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...